p53 +/- Hemizygous Knockout Mouse: Overview of Available Data

The performance of the p53 +/- transgenic (knockout) mouse model was evaluated through review of the data from 31 short-term carcinogenicity studies with 21 compounds tested as part of the International Life Sciences Institute's (ILSI) Alternatives to Carcinogenicity Testing (ACT) project, together with data from other studies which used comparable protocols. As expected based on the hypothesis for the model, a significant number (12/16 or 75%) of the genotoxic human and/or rodent carcinogens tested were positive and the positive control, p-cresidine, gave reproducible responses across laboratories (18/19 studies positive in bladder). An immunosuppressive human carcinogen, cyclosporin A, was positive for lymphomas but produced a similar response in wild type mice. Two hormones that are human tumorigens, diethylstilbestrol and 17β-estradiol, gave positive and equivocal results, respectively, in the pituitary with p53-defi cient mice showing a greater incidence of proliferative lesions than wild type. None of the 22 nongenotoxic rodent carcinogens that have been tested produced a positive response but 2 compounds in this category, chloroform and diethylhexylphthalate, were judged equivocal based on effects in liver and kidney respectively. Four genotoxic noncarcinogens and 6 nongenotoxic, noncarcinogens were also negative. In total (excluding compounds with equivocal results), 42 of 48 compounds or 88% gave results that were concordant with expectations. The technical lessons learned from the ILSI ACT-sponsored testing in the p53+/- model are discussed.

[1]  Lawrence A. Donehower,et al.  A mutant p53 transgene accelerates tumour development in heterozygous but not nullizygous p53–deficient mice , 1995, Nature Genetics.

[2]  L. Donehower.  The p53-deficient mouse: a model for basic and applied cancer studies. , 1996, Seminars in cancer biology.

[3]  L. Donehower,et al.  Reduction of p53 gene dosage does not increase initiation or promotion but enhances malignant progression of chemically induced skin tumors , 1993, Cell.

[4]  R. Tennant.  Evaluation and validation issues in the development of transgenic mouse carcinogenicity bioassays. , 1998, Environmental health perspectives.

[5]  R. Tennant,et al.  Identifying chemical carcinogens and assessing potential risk in short-term bioassays using transgenic mouse models. , 1995, Environmental health perspectives.

[6]  H. Tsuda,et al.  Heterozygous p53-deficient mice are not susceptible to 2-amino-3,8-dimethylimidazo[4,5-f]quinoxaline (MeIQx) carcinogenicity. , 1999, Cancer letters.

[7]  L. Donehower,et al.  Infrequent p53 mutations in 7,12‐dimethylbenz[a]anthracene–induced mammary tumors in BALB/c and p53 hemizygous mice , 1994, Molecular carcinogenesis.

[8]  J. Contrera,et al.  In vivo transgenic bioassays and assessment of the carcinogenic potential of pharmaceuticals. , 1998, Environmental health perspectives.

[9]  H. Masuda,et al.  Testing for carcinogenicity of pharmaceuticals. , 1996, The Journal of toxicological sciences.

[10]  J. Haseman,et al.  The National Toxicology Program Evaluation of Genetically Altered Mice as Predictive Models for Identifying Carcinogens , 1998, Toxicologic pathology.

[11]  R. Tennant,et al.  Review Article: Use of Transgenic Animals for Carcinogenicity Testing: Considerations and Implications for Risk Assessment , 2000 .

[12]  R. Tennant,et al.  Responses of transgenic mouse lines p53(+/-) and Tg.AC to agents tested in conventional carcinogenicity bioassays. , 2000, Toxicological sciences : an official journal of the Society of Toxicology.

[13]  R. Tennant,et al.  Evaluation of transgenic mouse bioassays for identifying carcinogens and noncarcinogens. , 1996, Mutation research.

[14]  M. Aardema,et al.  The low pH Syrian hamster embryo (SHE) cell transformation assay: a revitalized role in carcinogen prediction. , 1996, Mutation research.

[15]  S. Stasiewicz,et al.  Phenolphthalein Induces Thymic Lymphomas Accompanied by Loss of the p53 Wild Type Allele in Heterozygous p53-Deficient (±) Mice , 1997, Toxicologic pathology.

[16]  E. Debruyne,et al.  The p53 heterozygous knockout mouse as a model for chemical carcinogenesis in vascular tissue. , 1999, Environmental Health Perspectives.

[17]  L. Donehower,et al.  Effects of genetic background on tumorigenesis in p53‐deficient mice , 1995, Molecular carcinogenesis.

[18]  S. Wakana,et al.  Rapid induction of uterine tumors with p53 point mutations in heterozygous p53-deficient CBA mice given a single intraperitoneal administration of N-ethyl-N-nitrosourea. , 2000, Carcinogenesis.

[19]  D. Casciano,et al.  Evaluation of the transgenic p53+/- mouse for detecting genotoxic liver carcinogens in a short-term bioassay. , 1999, Cancer letters.

[20]  J. Haseman,et al.  Spontaneous and Chemically Induced Proliferative Lesions in Tg.AC Transgenic and p53-Heterozygous Mice , 1998, Toxicologic pathology.

[21]  D. Pinkel,et al.  The role of p53 loss in genomic instability and tumor progression in a murine mammary cancer model. , 1996, Progress in clinical and biological research.

[22]  R. Tennant,et al.  Use of transgenic animals for carcinogenicity testing: considerations and implications for risk assessment. , 2000, Toxicologic pathology.

[23]  A. Balmain,et al.  p53-deficient mice are extremely susceptible to radiation-induced tumorigenesis , 1994, Nature Genetics.

[24]  D. Morris,et al.  Phenobarbital Does Not Promote Hepatic Tumorigenesis in a Twenty-Six-Week Bioassay in p53 Heterozygous Mice , 1998, Toxicologic pathology.

[25]  R. Stoll,et al.  Oxymetholone : III . Evaluation in the p 53 + /-Transgenic Mouse Model * , 2007 .

[26]  C. Kemp.  Hepatocarcinogenesis in p53‐deficient mice , 1995, Molecular carcinogenesis.

[27]  R. Storer.  Current status and use of short/medium term models for carcinogenicity testing of pharmaceuticals--scientific perspective. , 2000, Toxicology letters.

[28]  R E Stoll,et al.  Transponder-Induced Sarcoma in the Heterozygous p53+/- Mouse , 1999, Toxicologic pathology.

[29]  S. Fukushima,et al.  High susceptibility of p53(+/-) knockout mice in N-butyl-N-(4-hydroxybutyl)nitrosamine urinary bladder carcinogenesis and lack of frequent mutation in residual allele. , 1998, Cancer research.

[30]  M. Kripke,et al.  p53 protects against skin cancer induction by UV-B radiation , 1999, Oncogene.

[31]  L. Donehower,et al.  Spontaneous and carcinogen–induced tumorigenesis in p53–deficient mice , 1993, Nature Genetics.

[32]  L. Donehower,et al.  Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours , 1992, Nature.

[33]  D. Pinkel,et al.  Retention of wild‐type p53 in tumors from p53 heterozygous mice: reduction of p53 dosage can promote cancer formation , 1998, The EMBO journal.

[34]  S. Fukushima,et al.  Dose-dependent induction of aberrant crypt foci in the colons but no neoplastic lesions in the livers of heterozygous p53-deficient mice treated with low dose 2-amino-3-methylimidazo [4,5-f]quinoline. , 1999, Cancer letters.

[35]  D. Robinson.  The International Life Sciences Institute's Role in the Evaluation of Alternative Methodologies for the Assessment of Carcinogenic Risk , 1998, Toxicologic pathology.

[36]  Mark D. Hoover,et al.  Carcinogenic Responses of Transgenic Heterozygous p53 Knockout Mice to Inhaled 239PuO2 or Metallic Beryllium , 1998, Toxicologic pathology.